Hopp til hovedinnhold
Diabetes type 1 starter akutt med høyt blodsukker og symptomer som tørste, økt urinproduksjon, vekttap og nedsatt allmenntilstand.
Diabetes type 1 starter akutt med høyt blodsukker og symptomer som tørste, økt urinproduksjon, vekttap og nedsatt allmenntilstand.

Diabetes type 1

Diabetes type 1 er en insulinmangelsykdom. Kroppens immunforsvar ødelegger egne insulinproduserende celler, og man må få tilført insulin via injeksjoner eller insulinpumpe.

Sist revidert:
QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/hormoner-og-naring/diabetes-type-1/type-1-diabetes/ 

Hva er diabetes type 1?

Forekomst

Årsaker

Diagnosen

Akuttfase med høyt blodsukker

Lab-undersøkelser

Behandling

Kosthold

Mosjon

Insulinbehandling

Prognose

Oppfølging

Egenkontroll

Kontroller på poliklinikken/legekontoret

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Diabetes type 1. Referanselisten for dette dokumentet vises nedenfor.

  1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014 Jan 4; 383(9911): 69–82. www.ncbi.nlm.nih.gov 
  2. Helsedirektoratet. Nasjonal faglig retningslinje for diabetes. Sist oppdatert 15.04.2020. helsedirektoratet.no 
  3. Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M. The challenge of modulating β-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2019;7(1):52-64. PMID: 30528099. PubMed 
  4. Kakleas K, Karayianni C, Critselis E, et al. The prevalence and risk factors for coeliac disease among children and adolescents with type 1 diabetes mellitus. Diabetes Res Clin Pract 2010;90:202-208. PubMed 
  5. Davis AK, DuBose SN, Haller MJ, et al. Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care December 17, 2014. Published online before print December 17, 2014, . doi:10.2337/dc14-1952 DOI 
  6. Wang L, Lovejoy NF, Faustman DL. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 2012; 35: 465-70. pmid:22355018 PubMed 
  7. Atkinson MA, Eisenbarth GS. Type 1A diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358: 221-9. PubMed 
  8. Harjutsalo V, Podar T, Tuomilehto J. Cumulative incidence of type 1 diabetes in 10,168 siblings of Finnish young-onset type 1 diabetic patients. Diabetes 2005; 54: 563-69. PubMed 
  9. Norris JM, Beaty B, Klingensmith G, Yu L, Hoffman M, Chase HP, et al. Lack of association between early exposure to cow's milk protein and -cell autoimmunity: diabetes autoimmunity study in the young (DAISY). JAMA 1996;276: 609-14. Journal of the American Medical Association 
  10. Hober D, Sauter P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat Rev Endocrinol 2010;6:279-289 PubMed 
  11. Norris JM, Barriga K, Klingensmith G, Hoffman M, Eisenbarth GS, Erlich HA, et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 2003;290: 1713-20. Journal of the American Medical Association 
  12. Ziegler AG, Schmid S, Huber D, Hummel M, Bonifacio E. Early infant feeding and risk of developing type 1A diabetes-associated autoantibodies. JAMA 2003;290: 1721-8. Journal of the American Medical Association 
  13. Lombardi A, Tsomos E, Hammerstad SS, Tomer Y. Interferon alpha: The key trigger of type 1 diabetes. J Autoimmun. 2018;94:7-15. PMID: 30115527. PubMed 
  14. Fousteri G, Dave Jhatakia A. Viral Infections and Autoimmune Disease: Roles of LCMV in Delineating Mechanisms of Immune Tolerance. Viruses. 2019;11(10):885. Published 2019 Sep 21. PMID: 31546586. PubMed 
  15. Usher-Smith JA, Thompson MJ, Sharp SJ, Walter FM. Factors associated with the presence of diabetic ketoacidosis at diagnosis of diabetes in children and young adults; a systematic review. BMJ 2011; 343: d4092. BMJ (DOI) 
  16. Crawford F, Cezard G, Chappell FM, et al. A systematic review and individual patient data meta-analysis of prognostic factors for foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS). Health Technol Assess. 2015 Jul;19(57):1-210. PubMed 
  17. Hals IK, Fiskvik Fleiner H, Reimers N, et al. Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults: Results from a 21-month randomized trial.. Diabetes Obes Metab 2019; 21: 2219-27. pmid:31148332 PubMed 
  18. Lind M et al. HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. BMJ 2019 Aug 28; 366:l4894. pmid: 31462492 PubMed 
  19. Birkeland KI. Insulinbehandling ved type 1-diabetes hos voksne. Tidsskr Nor Legeforen 2006; 126: 776-8. PubMed 
  20. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-67. Journal of the American Medical Association 
  21. Boyko EJ, Zelnick LR, Braffet B, et al. Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 2022; 45: 357-364. pmid:35007329 PubMed 
  22. Nathan DM, Cleary PA, Backlund JY, et al, for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N Engl J Med 2005; 353: 2643-53. New England Journal of Medicine 
  23. Musso G, Sircana A, Saba F, et al. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression. PLoS Med. 2020 Dec 29;17(12):e1003461. PMID: 33373368 PubMed 
  24. Mahase E. Type 1 diabetes drug was withdrawn because of a “commercial conflict of interest,” charity argues. BMJ News 2022; 376:o373. Published 14 February 2022. doi:10.1136/bmj.o373 DOI 
  25. Avgerinos I, Manolopoulos A, Michailidis T, et al. Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. Diabetes Obes Metab. 2020. PMID: 33300282 PubMed 
  26. Thalange N, Bereket A, Larsen J, et al. Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial. Diabet Med 2013 Feb; 30(2): 216-25. PubMed 
  27. Lane W, Bailey TS, Gerety G, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes The SWITCH 1 Randomized Clinical Trial. JAMA 2017; 318: 33-44. doi:10.1001/jama.2017.7115 DOI 
  28. Davies MJ, Gross JL, Ono Y, et al. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab. 2014 Apr 7.
  29. Nørgaard K, Sohlberg A, Goodall G. Omkostningseffektivitet ved behandling af type 1-diabetes med insulinpumpe. Ugeskr Læger 2010; 172: 2020. Ugeskrift for Læger 
  30. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of Sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med, June 29, 2010.
  31. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes. N Engl J Med 2014. doi:DOI: 10.1056/NEJMoa1314474 DOI 
  32. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med 2019; 381: 1707-17. pmid:31618560 PubMed 
  33. Burnside MJ, Lewis DM, Crocket HR, et al. Open-Source Automated Insulin Delivery in Type 1 Diabetes. N Engl J Med 2022; 387: 869-881. pmid:36069869 PubMed 
  34. Hussain MA, Theise ND. Stem-cell therapy for diabetes mellitus. Lancet 2004; 364: 203-5. PubMed 
  35. Chetboun M, Drumez E, Ballou C, et al. Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from the Collaborative Islet Transplant Registry. Lancet Diabetes Endocrinol 2023; 11: 391-401. pmid:37105208 PubMed 
  36. Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group . Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes A Randomized Clinical Trial. JAMA 2017; 318: 1891-902. pmid:29164254 PubMed 
  37. The Diabetes Virus Detection and Intervention Trial. Nettside besøkt 06.12.20. forskningsprosjekter.ihelse.net 
  38. Gagnum V, Saeed M, Stene LC, et al. Low Incidence of End-Stage Renal Disease in Childhood-Onset Type 1 Diabetes Followed for Up to 42 Years.. Diabetes Care 2018; 41: 420-5. pmid:29025877 PubMed 
  39. Toni G, Berioli MG, Cerquiglini L, et al. Eating Disorders and Disordered Eating Symptoms in Adolescents with Type 1 Diabetes. Nutrients. 2017;9(8):906. Published 2017 Aug 19. PMID: 28825608. PubMed 
  40. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169:1307. PubMed 
  41. Finne P, Reunanen A, Stenman S, Groop P-H, Grönhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294: 1782-7. PubMed 
  42. Holte KB, Svanteson M, Hanssen KF, Haig Y, Solheim S, Berg TJ. Undiagnosed coronary artery disease in long-term type 1 diabetes. The Dialong study. J Diabetes Complications. 2019;33(5):383-389. PMID: 30846232 PubMed 
  43. Lind M, Bounias I, Olsson M, et al. Glycaemic control and incidence of heart failure in 20985 patients with type 1 diabetes: an observational study. Lancet 2011; 378: 140-6. PubMed 
  44. Lind M, Svensson A-M, Kosiborod M, et al. Glycemic Control and Excess Mortality in Type 1 Diabetes. N Engl J Med 2014; 371: 1972-82. doi:10.1056/NEJMoa1408214 DOI 
  45. Matuleviciene-Anängen V, Rosengren A, Svensson AM, et al. Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes. Heart 2017. pmid:28710186 PubMed 
  46. Huxley RR, Peters SA, Mishra GD, Woodward M. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3:198-206. doi:10.1016/S2213-8587(14)70248-7 DOI 
  47. Edwards J, Stapley S. Debridement of diabetic foot ulcers. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003556. DOI: 10.1002/14651858.CD003556.pub2. DOI 
  48. Wagner S, Nørgaard K, Willaing I, et al. Upper-extremity impairments in type 1 diabetes: Results from a controlled nationwide study. Diabetes Care 2023; 46: 1204-1208. pmid:37000698 PubMed 
  49. Larkin ME, Barnie A, Braffett BH, et al. Musculoskeletal Complications in Type 1 Diabetes. Diabetes Care. 2014 Apr 10.
  50. Juel NG, Brox JI, Brunborg C, et al. Very High Prevalence of Frozen Shoulder in Patients With Type 1 Diabetes of ≥45 Years' Duration: The Dialong Shoulder Study. Arch Phys Med Rehabil 2017; 98: 1551-9. pmid:28219686 PubMed 
  51. Perkins BA, Ficociello LH, Silva KH. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348: 2285-93. pmid:12788992 PubMed 
  52. Cooper MN, de Klerk NH, Jones TW, Davis EA.. Clinical and demographic risk factors associated with mortality during early adulthood in a population-based cohort of childhood-onset type 1 diabetes. Diabet Med 2014; 31(12): 1550-8. doi:10.1111/dme.12522 DOI 
  53. Katz M, Laffel L. Mortality in type 1 diabetes in the current era. Two steps forward, one step backward. JAMA. 2015;313(1):35-36 . doi:10.1001/jama.2014.16327 DOI 
  54. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population. Diabetologia. 2010;53(11):2312-2319. PubMed 
  55. Groop PH, Thomas MC, Moran JL, et al; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58(7):1651-1658. PubMed 
  56. Hallström S, Wijkman MO, Ludvigsson J, et al. Risk factors, mortality trends and cardiovasuclar diseases in people with Type 1 diabetes and controls: A Swedish observational cohort study. Lancet Reg Health Eur. 2022;21:100469. Published 2022 Jul 22. doi:10.1016/j.lanepe.2022.100469. PMID: 35898332 PubMed 
  57. DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. doi:10.1001/jama.2014.16107. DOI 
  58. Havas S, Donner T. Tight control of type 1 diabetes: Recommendations for patients. Am Fam Physician 2006; 74: 971-8. PubMed 
  59. Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015;313(1):37-44. . doi:10.1001/jama.2014.16425 DOI 
  60. Krogvold L, Edwin B, Buanes T, et al. Detection of a low-grade enteroviral infection in the islets of langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes 2015; 64: 1682-7. pmid:25422108 PubMed 
  61. Abbasi J. Type 1 Diabetes Advances Could Pave Way for Prevention. Medical News & Perspectives. August 2019
  62. Julsrud Berg T. Diabetes mellitus. Norsk legemiddelhåndbok, sist endret 19.09.2018. www.legemiddelhandboka.no